In addition to demonstrated efficacy in the already established setting of MBC, nab-paclitaxel appears to be an effective and well-tolerated neoadjuvant therapy for patients with early-stage breast cancer, particularly the HER2-positive and TNBC subgroups. This evidence concerns the gene ERBB2 and breast carcinoma.